Mycosis fungoides primary prevention

	Mycosis fungoides Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Mycosis Fungoides from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
X-Ray
CT Scan
MRI
Echocardiography and Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Mycosis fungoides primary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Mycosis fungoides primary prevention All Images X-rays Echo and Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Mycosis fungoides primary prevention
CDC on Mycosis fungoides primary prevention
Mycosis fungoides primary prevention in the news
Blogs on Mycosis fungoides primary prevention
Directions to Hospitals Treating Mycosis fungoides
Risk calculators and risk factors for Mycosis fungoides primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]

Overview

There are no established measures for the secondary prevention of mycosis fungoides but recommended that effective measures for the secondary prevention of mycosis fungoides is follow up patients with active or progressive disease, every 4–6 weeks.

↑ A. S. Whittemore, E. A. Holly, I. M. Lee, E. A. Abel, R. M. Adams, B. J. Nickoloff, L. Bley, J. M. Peters & C. Gibney (1989). "Mycosis fungoides in relation to environmental exposures and immune response: a case-control study". Journal of the National Cancer Institute. 81 (20): 1560–1567. PMID 2795681. Unknown parameter |month= ignored (help)
↑ Hall WW, Liu CR, Schneewind O, Takahashi H, Kaplan MH, Röupe G, Vahlne A (July 1991). "Deleted HTLV-I provirus in blood and cutaneous lesions of patients with mycosis fungoides". Science. 253 (5017): 317–20. PMID 1857968.
↑ S. K. Ghosh, J. T. Abrams, H. Terunuma, E. C. Vonderheid & E. DeFreitas (1994). "Human T-cell leukemia virus type I tax/rex DNA and RNA in cutaneous T-cell lymphoma". Blood. 84 (8): 2663–2671. PMID 7522638. Unknown parameter |month= ignored (help)